JPRN-UMIN000001574已完成未知
Mie Study of Clopidogrel Low Responder in Atherothrombotic Disease Patients with/without Diabetes - Mie Study of Clopidogrel Low Responder in Atherothrombotic Disease Patients with/without Diabetes (McLORDD Study)
McLORDD, Coordinating Office0 个研究点目标入组 250 人开始时间: 2008年12月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
CYP2C19 loss-of-function genotype is associated with more frequent high platelet reactivity, as assessed by ADP-specific platelet function tests, in Japanese patients.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients before operation 2) Cerebral infraction without embolization from the heart 3) Taking following drugs, warfarin, thrombolytic agents, heparin, etc. anti-platelet drugs except aspirin, clopidogrel or cilostazol (e.g., sarpogrelate, diryridamole, EPA, etc.) 4) Not eligible determind by the responding physician
研究者
相似试验
已完成
不适用
Implementation of CYP2C19 Genotyping to Guide Antiplatelet TherapyCoronary Artery DiseaseNCT02724319University of Florida1,000
已完成
不适用
The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke PatientsPlatelet Aggregation InhibitorsNCT02711410National Cerebral and Cardiovascular Center, Japan518
已完成
不适用
Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and OmeprazoleCoronary Artery DiseaseNCT01094275Neil Kleiman, MD75
已完成
4 期
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics ProfileCoronary Artery Disease (CAD)NCT05516784Universiti Sains Malaysia80
Unknown
不适用
Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition StatusPRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGRELNCT01210248Assaf-Harofeh Medical Center500